Literature DB >> 11575459

Serum collagen type VI and XIV and hyaluronic acid as early indicators for altered connective tissue turnover in alcoholic liver disease.

F Stickel1, R Urbaschek, D Schuppan, G Poeschl, C Oesterling, C Conradt, R S McCuskey, U A Simanowski, H K Seitz.   

Abstract

Hepatic fibrosis in alcoholic liver disease often heralds progression to cirrhosis and, therefore, noninvasive parameters are required for early diagnosis and follow-up. Collagens VI and XIV, procollagen-III-N-propeptide, hyaluronic acid, and active transforming growth factor-beta1 (TGF-beta1) were measured in healthy volunteers, patients with alcoholic cirrhosis, and heavy drinkers without cirrhosis. Noncirrhotic alcoholics were assigned to two groups with either normal aspartate aminotransferase or levels > or = 2 normal. Collagens VI and XIV were elevated in all alcoholic patients compared to controls (P < 0.0001, all instances). Procollagen-III-N-propeptide and hyaluronic acid levels were higher in alcoholic patients with elevated liver enzymes and in cirrhotics as compared to controls. Procollagen-III-N-propeptide revealed a significant correlation with serum levels of TGF-beta1 (P < 0.0001). Collagens VI, and XIV, procollagen-III-N-propeptide, and hyaluronic acid appear to be sensitive markers indicating fibrotic transformation in alcoholics. The correlation between procollagen-III-N-propeptide and TGF-beta1 emphasizes its role in hepatic fibrogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11575459     DOI: 10.1023/a:1010616021659

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  41 in total

Review 1.  Hepatic fibrosis - therapeutic strategies.

Authors:  D Schuppan; D Strobel; E G Hahn
Journal:  Digestion       Date:  1998 Jul-Aug       Impact factor: 3.216

Review 2.  Connective tissue biology and hepatic fibrosis: report of a conference.

Authors:  D M Bissell; S L Friedman; J J Maher; F J Roll
Journal:  Hepatology       Date:  1990-03       Impact factor: 17.425

3.  Prediction of liver fibrosis according to serum collagen VI level in children with cystic fibrosis.

Authors:  B Gerling; M Becker; D Staab; D Schuppan
Journal:  N Engl J Med       Date:  1997-05-29       Impact factor: 91.245

4.  Serum procollagen peptides and collagen type VI for the assessment of activity and degree of hepatic fibrosis in schistosomiasis and alcoholic liver disease.

Authors:  M Shahin; D Schuppan; R Waldherr; J Risteli; L Risteli; E R Savolainen; C Oesterling; H M Abdel Rahman; A M el Sahly; S M Abdel Razek
Journal:  Hepatology       Date:  1992-04       Impact factor: 17.425

5.  The integrated value of serum procollagen III peptide over time predicts hepatic hydroxyproline content and stainable collagen in a model of dietary cirrhosis in the rat.

Authors:  M J Ruwart; K F Wilkinson; B D Rush; T J Vidmar; K M Peters; K S Henley; H D Appelman; K Y Kim; D Schuppan; E G Hahn
Journal:  Hepatology       Date:  1989-11       Impact factor: 17.425

6.  Connective tissue metabolism and alcohol intake in alcoholic liver disease.

Authors:  O Niemelä; J Risteli; J E Blake; L Risteli; K V Compton; H Orrego
Journal:  Alcohol Alcohol Suppl       Date:  1991

7.  Liver fibrosis in alcoholics. Detection by Fab radioimmunoassay of serum procollagen III peptides.

Authors:  S Sato; T Nouchi; T M Worner; C S Lieber
Journal:  JAMA       Date:  1986-09-19       Impact factor: 56.272

Review 8.  Transforming growth factor-beta (TGF-beta): a key-role in liver fibrogenesis.

Authors:  P Bedossa; V Paradis
Journal:  J Hepatol       Date:  1995       Impact factor: 25.083

9.  Serum concentrations of the carboxyterminal cross-linking domain of procollagen type IV (NC1) and the aminoterminal propeptide of procollagen type III (PIIIP) in chronic liver disease.

Authors:  A Hayasaka; D Schuppan; K Ohnishi; K Okuda; E G Hahn
Journal:  J Hepatol       Date:  1990-01       Impact factor: 25.083

10.  Regulation of extracellular matrix synthesis by transforming growth factor beta 1 in human fat-storing cells.

Authors:  A Casini; M Pinzani; S Milani; C Grappone; G Galli; A M Jezequel; D Schuppan; C M Rotella; C Surrenti
Journal:  Gastroenterology       Date:  1993-07       Impact factor: 22.682

View more
  16 in total

1.  Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes.

Authors:  Morten A Karsdal; Kim Henriksen; Federica Genovese; Diana J Leeming; Mette J Nielsen; Bente J Riis; Claus Christiansen; Inger Byrjalsen; Detlef Schuppan
Journal:  Diabetologia       Date:  2016-09-08       Impact factor: 10.122

Review 2.  Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches.

Authors:  Elisabetta Mormone; Joseph George; Natalia Nieto
Journal:  Chem Biol Interact       Date:  2011-07-22       Impact factor: 5.192

Review 3.  Alcoholic liver disease.

Authors:  Helmut K Seitz; Ramon Bataller; Helena Cortez-Pinto; Bin Gao; Antoni Gual; Carolin Lackner; Philippe Mathurin; Sebastian Mueller; Gyongyi Szabo; Hidekazu Tsukamoto
Journal:  Nat Rev Dis Primers       Date:  2018-08-16       Impact factor: 52.329

Review 4.  Non-invasive diagnosis of alcoholic liver disease.

Authors:  Sebastian Mueller; Helmut Karl Seitz; Vanessa Rausch
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

5.  Relationship between clinical and pathologic findings in patients with chronic liver diseases.

Authors:  Lun-Gen Lu; Min-De Zeng; Yi-Min Mao; Ji-Qiang Li; De-Kai Qiu; Jing-Yuan Fang; Ai-Ping Cao; Mo-Bin Wan; Cheng-Zhong Li; Jun Ye; Xiong Cai; Cheng-Wei Chen; Ji-Yao Wang; Shan-Ming Wu; Jin-Shui Zhu; Xia-Qiu Zhou
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

Review 6.  Cocarcinogenic effects of alcohol in hepatocarcinogenesis.

Authors:  F Stickel; D Schuppan; E G Hahn; H K Seitz
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 7.  Current experimental perspectives on the clinical progression of alcoholic liver disease.

Authors:  Katja Breitkopf; Laura E Nagy; Juliane I Beier; Sebastian Mueller; Honglei Weng; Steven Dooley
Journal:  Alcohol Clin Exp Res       Date:  2009-07-23       Impact factor: 3.455

8.  Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters.

Authors:  Lun-Gen Lu; Min-De Zeng; Mo-Bin Wan; Cheng-Zhong Li; Yi-Min Mao; Ji-Qiang Li; De-Kai Qiu; Ai-Ping Cao; Jun Ye; Xiong Cai; Cheng-Wei Chen; Ji-Yao Wang; Shan-Ming Wu; Jin-Shui Zhu; Xia-Qiu Zhou
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

9.  Endotrophin, a multifaceted player in metabolic dysregulation and cancer progression, is a predictive biomarker for the response to PPARγ agonist treatment.

Authors:  Kai Sun; Jiyoung Park; Min Kim; Philipp E Scherer
Journal:  Diabetologia       Date:  2016-10-07       Impact factor: 10.122

10.  Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma.

Authors:  Diana Julie Leeming; Signe Holm Nielsen; Roslyn Vongsuvanh; Pruthviraj Uchila; Mette Juul Nielsen; Alexander L Reese-Petersen; David van der Poorten; Mohammed Eslam; Detlef Schuppan; Morten Asser Karsdal; Jacob George
Journal:  Hepat Oncol       Date:  2020-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.